Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Source filing unavailable
| Metric | Q1 2014 | Q1 2013 | Q1 2012 |
|---|---|---|---|
| Net Income | -$571.51K | -$492.68K | -$3.07M |
| EPS Diluted | -$0.01 | -$0.01 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
